Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms

Detalhes bibliográficos
Autor(a) principal: Burk, O.
Data de Publicação: 2012
Outros Autores: Piedade, R., Ghebreghiorghis, L., Fait, J. T., Nussler, A. K., Gil, J. P., Windshuegel, B., Schwab, M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/11846
Resumo: BACKGROUND AND PURPOSE Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drugdrug interactions. Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding. EXPERIMENTAL APPROACH A total of 21 selected antimalarials and 11 major metabolites were screened for binding to CAR isoforms using cellular and in vitro CAR-coactivator interaction assays, combined with in silico molecular docking. Identified ligands were further characterized by cell-based assays and primary human hepatocytes were used to elucidate induction of gene expression. KEY RESULTS Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2. Dihydroartemisinin and artesunate acted as weak inverse agonists of CAR1. While arteether showed the highest activities in vitro, it was less active than artemisinin in inducing hepatic CYP3A4 gene expression in hepatocytes. CONCLUSIONS AND IMPLICATIONS Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR). This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not. All these drugs are metabolized very rapidly, but only artemisinin is converted to an enzyme-inducing metabolite. For better understanding of pharmacokinetic drugdrug interaction possibilities, the inducing properties of artemisinin metabolites should be considered.
id RCAP_d93632d2c76ef4c2595e7e6c858c8076
oai_identifier_str oai:sapientia.ualg.pt:10400.1/11846
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoformsPregnane-X-receptorLigand-bindingForce-fieldHuman liverIn-vitroCarAntimalarialInductionCyp2B6Cytochrome-P450BACKGROUND AND PURPOSE Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drugdrug interactions. Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding. EXPERIMENTAL APPROACH A total of 21 selected antimalarials and 11 major metabolites were screened for binding to CAR isoforms using cellular and in vitro CAR-coactivator interaction assays, combined with in silico molecular docking. Identified ligands were further characterized by cell-based assays and primary human hepatocytes were used to elucidate induction of gene expression. KEY RESULTS Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2. Dihydroartemisinin and artesunate acted as weak inverse agonists of CAR1. While arteether showed the highest activities in vitro, it was less active than artemisinin in inducing hepatic CYP3A4 gene expression in hepatocytes. CONCLUSIONS AND IMPLICATIONS Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR). This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not. All these drugs are metabolized very rapidly, but only artemisinin is converted to an enzyme-inducing metabolite. For better understanding of pharmacokinetic drugdrug interaction possibilities, the inducing properties of artemisinin metabolites should be considered.German Federal Ministry of Education and Research (BMBF) HepatosSys network [0313081B, 0313080F, 0313080I]; Deutsche Forschungsgemeinschaft (Germany) [KE 1629/1-1]; Robert Bosch Foundation, Stuttgart, GermanyWiley-BlackwellSapientiaBurk, O.Piedade, R.Ghebreghiorghis, L.Fait, J. T.Nussler, A. K.Gil, J. P.Windshuegel, B.Schwab, M.2018-12-07T14:58:05Z2012-102012-10-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/11846eng0007-118810.1111/j.1476-5381.2012.02033.xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:23:43Zoai:sapientia.ualg.pt:10400.1/11846Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:03:17.520732Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
title Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
spellingShingle Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
Burk, O.
Pregnane-X-receptor
Ligand-binding
Force-field
Human liver
In-vitro
Car
Antimalarial
Induction
Cyp2B6
Cytochrome-P450
title_short Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
title_full Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
title_fullStr Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
title_full_unstemmed Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
title_sort Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
author Burk, O.
author_facet Burk, O.
Piedade, R.
Ghebreghiorghis, L.
Fait, J. T.
Nussler, A. K.
Gil, J. P.
Windshuegel, B.
Schwab, M.
author_role author
author2 Piedade, R.
Ghebreghiorghis, L.
Fait, J. T.
Nussler, A. K.
Gil, J. P.
Windshuegel, B.
Schwab, M.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Burk, O.
Piedade, R.
Ghebreghiorghis, L.
Fait, J. T.
Nussler, A. K.
Gil, J. P.
Windshuegel, B.
Schwab, M.
dc.subject.por.fl_str_mv Pregnane-X-receptor
Ligand-binding
Force-field
Human liver
In-vitro
Car
Antimalarial
Induction
Cyp2B6
Cytochrome-P450
topic Pregnane-X-receptor
Ligand-binding
Force-field
Human liver
In-vitro
Car
Antimalarial
Induction
Cyp2B6
Cytochrome-P450
description BACKGROUND AND PURPOSE Widespread resistance to antimalarial drugs requires combination therapies with increasing risk of pharmacokinetic drugdrug interactions. Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding. EXPERIMENTAL APPROACH A total of 21 selected antimalarials and 11 major metabolites were screened for binding to CAR isoforms using cellular and in vitro CAR-coactivator interaction assays, combined with in silico molecular docking. Identified ligands were further characterized by cell-based assays and primary human hepatocytes were used to elucidate induction of gene expression. KEY RESULTS Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2. Dihydroartemisinin and artesunate acted as weak inverse agonists of CAR1. While arteether showed the highest activities in vitro, it was less active than artemisinin in inducing hepatic CYP3A4 gene expression in hepatocytes. CONCLUSIONS AND IMPLICATIONS Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR). This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not. All these drugs are metabolized very rapidly, but only artemisinin is converted to an enzyme-inducing metabolite. For better understanding of pharmacokinetic drugdrug interaction possibilities, the inducing properties of artemisinin metabolites should be considered.
publishDate 2012
dc.date.none.fl_str_mv 2012-10
2012-10-01T00:00:00Z
2018-12-07T14:58:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/11846
url http://hdl.handle.net/10400.1/11846
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0007-1188
10.1111/j.1476-5381.2012.02033.x
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133267132153856